BofA raised the firm’s price target on Cytokinetics (CYTK) to $56 from $52 and keeps a Neutral rating on the shares. The firm, which tells investors that the company “laid out a strong case” for aficamten over an in-depth discussion during the firm’s SF Bus Tour, doesn’t disagree that “the data for the next-gen CMI look very competitive,” but it would argue debate remains on execution.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Promising Trial Results and Safety Profile of Aficamten Boost Cytokinetics’ Stock Outlook
- Promising Data from HFSA and Long-term Efficacy of Aficamten Lead to Buy Rating for Cytokinetics
- Cytokinetics’ Aficamten Shows Superior Efficacy in Phase 3 MAPLE-HCM Trial, Boosting Stock Outlook
- Cytokinetics presents data related to aficamten at HFSA Meeting 2025
- Positive Outlook and Buy Rating for Cytokinetics Amid Strategic Advancements and Financial Strengthening